Menu Search
Equities

InnoCare Pharma Ltd

33C:STU

InnoCare Pharma Ltd

Actions
  • Price (EUR)0.83
  • Today's Change-0.04 / -4.60%
  • Shares traded0.00
  • 1 Year change+4.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year InnoCare Pharma Ltd grew revenues 18.09% from 625.40m to 738.54m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -886.59m to -631.26m.
Gross margin85.59%
Net profit margin-62.04%
Operating margin-58.08%
Return on assets-4.88%
Return on equity-6.55%
Return on investment-6.20%
More ▼

Cash flow in CNYView more

In 2023, InnoCare Pharma Ltd did not generate a significant amount of cash. However, Cash Flow from Investing totalled 666.91m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 671.34m for operations while cash generated from financing totalled 1.31m.
Cash flow per share-0.2464
Price/Cash flow per share--
Book value per share4.23
Tangible book value per share4.20
More ▼

Balance sheet in CNYView more

InnoCare Pharma Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.54% of the market capitalization can be attributed to its 8.22bn and debt could be paid in full if management chose.
Current ratio3.82
Quick ratio3.77
Total debt/total equity0.2008
Total debt/total capital0.1667
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.